Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Work In Process (2021 - 2024)

RedHill Biopharma has reported Work In Process over the past 4 years, most recently at $308000.0 for Q4 2024.

  • Quarterly Work In Process rose 32.19% to $308000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $308000.0 through Dec 2024, up 32.19% year-over-year, with the annual reading at $308000.0 for FY2024, 32.19% up from the prior year.
  • Work In Process was $308000.0 for Q4 2024 at RedHill Biopharma, up from $233000.0 in the prior quarter.
  • Over five years, Work In Process peaked at $5.2 million in Q4 2021 and troughed at $233000.0 in Q4 2023.
  • The 4-year median for Work In Process is $1.3 million (2022), against an average of $2.0 million.
  • Year-over-year, Work In Process plummeted 90.23% in 2023 and then soared 32.19% in 2024.
  • A 4-year view of Work In Process shows it stood at $5.2 million in 2021, then tumbled by 54.09% to $2.4 million in 2022, then plummeted by 90.23% to $233000.0 in 2023, then soared by 32.19% to $308000.0 in 2024.
  • Per Business Quant, the three most recent readings for RDHL's Work In Process are $308000.0 (Q4 2024), $233000.0 (Q4 2023), and $2.4 million (Q4 2022).